Carubicin hydrochloride
Based on 1 Customer Validation
Carubicin hydrochloride is a microbially-derived compound. Carubicin hydrochloride is an effective inhibitor of VHL-defective (VHL−/−) CCRCC cell proliferation. Carubicin hydrochloride also induces apoptosis by a mechanism independent of p53 or hypoxia-inducible factor HIF2. Carubicin hydrochloride has the potential for the research of cancer diseases.
For research use only. We do not sell to patients.
- Purity: 98.33%
- CAS No.: 52794-97-5
- Formula: C26H28ClNO10
- Molecular Weight:549.95
-
Storage:
4°C, sealed storage, away from moisture
* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)
-
Biological Activity
-
Chemical Information
-
Solvent & Solubility
- Purity & Documentation
- References
-
Help & FAQs
-
Anti-Infection Compound Library
HY-L002
-
Apoptosis Compound Library
HY-L003
-
Natural Product Library
HY-L021
-
Anti-Cancer Compound Library
HY-L025
-
Phenols Library
HY-L057
-
Microbial Metabolite Library
HY-L084
-
Anti-Cancer Natural Product Library
HY-L107
-
Heterocyclic Compound Library
HY-L138
-
Cell Death Library
HY-L162
-
Bioactive Compound Library Max
HY-L181
-
Natural Product Library Plus
HY-L021P
-
Natural Product and Natural Product-Like Compound Library
HY-L021M
-
Bioactive Compound Library
HY-L001
-
Non-Alcoholic Fatty Liver Disease (NAFLD) Compound Library
HY-L199
-
High-Throughput Bioactive Compound Library
HY-L205
-
High-Throughput Natural Product Library
HY-L206
-
Quinones Library
HY-L243
-
Mass Spectrometry Natural Product Library
HY-L262
Biological Activity
Chemical Information
-
CAS No. 52794-97-5
-
Appearance Solid
-
Molecular Weight 549.95
-
Formula C26H28ClNO10
-
Color Brown to red
-
SMILES
OC1=C2C(C(C3=C(O)C=CC=C3C2=O)=O)=C(O)C([C@H]4O[C@H]5C[C@@H]([C@@H]([C@@H](O5)C)O)N)=C1C[C@](O)(C4)C(C)=O.[H]Cl
-
Synonyms
Carminomycin hydrochloride; Carminomicin I hydrochloride
-
Structure Classification
-
Initial Source
bacterium Actinomadura carminata
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
4°C, sealed storage, away from moisture
* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)
Solvent & Solubility
DMSO : 62.5 mg/mL (113.65 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 2.08 mg/mL (3.78 mM); Clear solution
This protocol yields a clear solution of ≥ 2.08 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: ≥ 2.08 mg/mL (3.78 mM); Clear solution
This protocol yields a clear solution of ≥ 2.08 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
-
%DMSO +
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
-
%+
-
+%Tween-80 + +
-
%Saline +
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Working solution concentration: 0.22 mg/mL
Method for preparing stock solution: mg drug dissolved in μL DMSO. Stock solution concentration: mg/mL. * In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)
1. Take μL DMSO stock solution;
2. Add μL .
μL , mix evenly;
3. Then add μL Tween 80, mix evenly;
4. Then add μL
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
Purity & Documentation
-
Data Sheet (277 KB)
-
SDS (254 KB)
- English - EN (254 KB)
- Français - FR (254 KB)
- Deutsch - DE (254 KB)
- Norwegian - NO (254 KB)
- Español - ES (254 KB)
- Swedish - SV (254 KB)
- Italian - IT (254 KB)
- Portuguese - PT (254 KB)
-
Handling Instructions (2659 KB)
References
[1]. Woldemichael GM, et al. Carminomycin I is an apoptosis inducer that targets the Golgi complex in clear cell renal carcinoma cells. Cancer Res. 2011 Jan 1;71(1):134-42. [Content Brief]
[2]. Tevyashova AN, et al. Carminomycin, 14-hydroxycarminomycin and its novel carbohydrate derivatives potently kill human tumor cells and their multidrug resistant variants. J Antibiot (Tokyo). 2004 Feb;57(2):143-50. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 1.8183 mL | 9.0917 mL | 18.1835 mL | 45.4587 mL |
| 5 mM | 0.3637 mL | 1.8183 mL | 3.6367 mL | 9.0917 mL | |
| 10 mM | 0.1818 mL | 0.9092 mL | 1.8183 mL | 4.5459 mL | |
| 15 mM | 0.1212 mL | 0.6061 mL | 1.2122 mL | 3.0306 mL | |
| 20 mM | 0.0909 mL | 0.4546 mL | 0.9092 mL | 2.2729 mL | |
| 25 mM | 0.0727 mL | 0.3637 mL | 0.7273 mL | 1.8183 mL | |
| 30 mM | 0.0606 mL | 0.3031 mL | 0.6061 mL | 1.5153 mL | |
| 40 mM | 0.0455 mL | 0.2273 mL | 0.4546 mL | 1.1365 mL | |
| 50 mM | 0.0364 mL | 0.1818 mL | 0.3637 mL | 0.9092 mL | |
| 60 mM | 0.0303 mL | 0.1515 mL | 0.3031 mL | 0.7576 mL | |
| 80 mM | 0.0227 mL | 0.1136 mL | 0.2273 mL | 0.5682 mL | |
| 100 mM | 0.0182 mL | 0.0909 mL | 0.1818 mL | 0.4546 mL |
Powered by Bioz